

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 15/04/2015

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965019	1
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965021	2
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965033	3
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965045	4
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965058	5
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965060	6
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965072	7
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965084	8
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965096	9
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965108	10
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965110	11
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965122	12
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965134	13
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965146	14
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965159	15
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965161	16
<a href="#">CLOPIDOGREL RATIOPHARM</a>	EMEA/H/C/4006	B01AC04	clopidogrel	Teva Pharma B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043965173	17
EVARREST	EMEA/H/C/2515	B02BC30	Human fibrinogen/Human thrombin	Omrix Biopharmaceuticals N.V.	feb-14	19-feb-15	27-mar-15	20-apr-15	043011028	2
HERCEPTIN	EMEA/H/C/278/II/78/G	L01XC03	Trastuzumab	Roche Registration Limited	lug-14	06-feb-15	27-mar-15	20-apr-15	034949038	3
HOLOCLAR	pending	S01XA19	Ex vivo expanded autologous human corneal epithelial cells containing stem cells	Chiesi Farmaceutici S.P.A.	dic-14	19-feb-15	27-mar-15	20-apr-15	043909011	1
MEMANTINA ACCORD	EMEA/H/C/2766/IAin/2/G	N06DX01	Memantina	Accord Healthcare Limited	ND	19-feb-15	27-mar-15	20-apr-15	043171141	14
MEMANTINA ACCORD	EMEA/H/C/2766/IAin/2/G	N06DX01	Memantina	Accord Healthcare Limited	ND	19-feb-15	27-mar-15	20-apr-15	043171154	15
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010467	46
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010479	47
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010481	48
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010493	49
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010505	50
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010517	51
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010529	52
OPRYMEA	EMEA/H/C/941/X/17	N04BC05	Pramipexole	Krka, d. d., Novo mesto	dic-14	17-feb-15	27-mar-15	20-apr-15	041010531	53
REVLIMID	EMEA/H/C/717/X/73/G	L04AX04	Lenalidomide	Celgene Europe Limited	feb-15	19-feb-15	27-mar-15	20-apr-15	038016097	9
Tasermyt	EMEA/H/C/3968	V03AE02	sevelamer hydrochloride	Genzyme Europe B.V.	gen-15	26-feb-15	27-mar-15	20-apr-15	043907017	1
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906015	1
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906027	2
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906039	3
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906041	4
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906054	5
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906066	6
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906078	7
XADAGO	EMEA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906080	8

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 15/04/2015

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
XADAGO	EMA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906092	9
XADAGO	EMA/H/C/2396	Pending	safinamide	Zambon S.p.A.	dic-14	24-feb-15	27-mar-15	20-apr-15	043906104	10
XYDALBA	EMA/H/C/2840	J01XA04	Dalbavancin	Durata Therapeutics International B.V.	dic-14	19-feb-15	27-mar-15	20-apr-15	043908019	1

La responsabilità di qualsiasi onere e/o attività che l'Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all'immissione in commercio del medicinale, è totalmente a carico dell'Azienda stessa. L'ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.